chartexchange

Camurus receives approval in Canada for Oczyesa® XR, a once-monthly, self-administered treatment for acromegaly

Cision | Oct 12, 2026 3:00 AM EDT

Lund, Sweden — 12 October 2026 — Camurus (NASDAQ STO: CAMX) today announced that Health Canada has issued a Notice of Compliance (NOC) for Oczyesa[®] XR, octreotide subcutaneous depot, for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogs.[1]

"Oczyesa XR offers people with acromegaly sustained control of their disease with a once-monthly injection they can take themselves, at home, instead of relying on clinic visits. We look forward to the launch of Oczyesa XR in Canada and to making it available to patients",

Read original article